Dynamic changes in innate immune responses during direct‐acting antiviral therapy for <scp>HCV</scp> infection
Jacinta A. Holmes(Peter Doherty Institute), Raymond T. Chung(Harvard University), Pierre Tonnerre(Harvard University), Emily O. Dumas(AbbVie (United States)), Joelle Brown(MetroHealth), Maxwell Robidoux(Harvard University), Nadia Alatrakchi(Harvard University), Daniel Kvistad(Harvard University), Sakuni T. Silva(Harvard University), Jenna Gustafson(Harvard University), Charles Carlton‐Smith(Harvard University), Hongtao Zhang(Chinese Academy of Sciences), Daniel E. Cohen(AbbVie (United States)), Georg M. Lauer(Broad Institute), Nancy S. Shulman(AbbVie (United States)), Arthur Y. Kim(Harvard University)
Cited by 24
Related Papers
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|728
National Survey of Drug-Resistant Tuberculosis in China
|New England Journal of Medicine|2012|649
ErbB receptors: from oncogenes to targeted cancer therapies
|Journal of Clinical Investigation|2007|578